Santhera Pharmaceuticals Holding (SPHDF)
OTHER OTC:SPHDF
Want to see SPHDF full AI Analyst Report?
Total Valuation
Santhera Pharmaceuticals Holding has a market cap or net worth of $326.35M. The enterprise value is $325.03M.
Market Cap$326.35M
Enterprise Value$325.03M
Share Statistics
Santhera Pharmaceuticals Holding has 15,151,147 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,151,147
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Santhera Pharmaceuticals Holding’s return on equity (ROE) is 4.17 and return on invested capital (ROIC) is -34.49%.
Return on Equity (ROE)4.17
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-34.49%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee989.55K
Profits Per Employee-631.23K
Employee Count78
Asset Turnover0.52
Inventory Turnover2.52
Valuation Ratios
The current PE Ratio of Santhera Pharmaceuticals Holding is ―. Santhera Pharmaceuticals Holding’s PEG ratio is -1.37.
PE Ratio―
PS Ratio2.12
PB Ratio-13.88
Price to Fair Value-13.88
Price to FCF-4.71
Price to Operating Cash Flow-6.77
PEG Ratio-1.37
Income Statement
In the last 12 months, Santhera Pharmaceuticals Holding had revenue of 77.19M and earned -49.24M in profits. Earnings per share was -3.78.
Revenue77.19M
Gross Profit14.47M
Operating Income-37.82M
Pretax Income-49.05M
Net Income-49.24M
EBITDA-32.13M
Earnings Per Share (EPS)-3.78
Cash Flow
In the last 12 months, operating cash flow was -34.76M and capital expenditures -52.00K, giving a free cash flow of -34.81M billion.
Operating Cash Flow-34.76M
Free Cash Flow-34.81M
Free Cash Flow per Share-2.30
Dividends & Yields
Santhera Pharmaceuticals Holding pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.44
52-Week Price Change51.11%
50-Day Moving Average20.14
200-Day Moving Average16.30
Relative Strength Index (RSI)61.72
Average Volume (3m)37.00
Important Dates
Santhera Pharmaceuticals Holding upcoming earnings date is Sep 16, 2026, TBA (Not Confirmed).
Last Earnings DateApr 28, 2026
Next Earnings DateSep 16, 2026
Ex-Dividend Date―
Financial Position
Santhera Pharmaceuticals Holding as a current ratio of 1.29, with Debt / Equity ratio of -827.40%
Current Ratio1.29
Quick Ratio0.89
Debt to Market Cap0.59
Net Debt to EBITDA-2.34
Interest Coverage Ratio-3.27
Taxes
In the past 12 months, Santhera Pharmaceuticals Holding has paid 185.00K in taxes.
Income Tax185.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Santhera Pharmaceuticals Holding EV to EBITDA ratio is -7.45, with an EV/FCF ratio of -6.87.
EV to Sales3.10
EV to EBITDA-7.45
EV to Free Cash Flow-6.87
EV to Operating Cash Flow-6.88
Balance Sheet
Santhera Pharmaceuticals Holding has $22.44M in cash and marketable securities with $97.77M in debt, giving a net cash position of -$75.33M billion.
Cash & Marketable Securities$22.44M
Total Debt$97.77M
Net Cash-$75.33M
Net Cash Per Share-$4.97
Tangible Book Value Per Share-$5.82
Margins
Gross margin is 18.74%, with operating margin of -48.99%, and net profit margin of -63.79%.
Gross Margin18.74%
Operating Margin-48.99%
Pretax Margin-63.55%
Net Profit Margin-63.79%
EBITDA Margin-41.62%
EBIT Margin-48.99%
Analyst Forecast
The average price target for Santhera Pharmaceuticals Holding is $38.53, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$38.53
Price Target Upside72.95% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast111.79%
EPS Growth Forecast-15.01%